The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The Asia Pacific microinsurance market size reached US$ 2.7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 7.0 Billion by 2027, exhibiting a growth rate (CAGR) of 18.5% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Microinsurance is a microfinance division that provides insurance plans to the underserved and low-income sections of society. It aids in providing insurance and other products and services at low premiums that are utilized for risk protection and relief against distress, misfortune, and other contingent events. Microinsurance offers tailor-made plans that meet the customer’s needs and covers property risks against crops, cattle and fires. It merges various small financial units that are formed into one massive structure to prevent unexpected losses and exorbitant interest rates. Nowadays, microinsurance products are delivered via various institutional channels such as licensed insurers, healthcare providers, microfinance institutions, community-based organizations, and non-governmental organizations.
The Asia Pacific represents one of the largest markets for microinsurance, primarily driven by the increasing demand for microinsurance products and services in developing countries such as India and China. This is due to the small installments of premium amounts for people from a poor financial background. Besides this, the growing interest of various stakeholders, such as NGOs, financial institutions and donors, in adding microfinance as an adaptation measure represents another factor propelling the market growth. Moreover, microinsurance offers a promising alternative for poor women to manage risk and use their assets more productively.
IMARC Group provides an analysis of the key trends in each sub-segment of the Asia Pacific microinsurance market report, along with forecasts at the regional and country level from 2022-2027. Our report has categorized the market based on product type, provider and model type.
Breakup by Product Type:
Breakup by Provider:
Breakup by Model Type:
Breakup by Country:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
|Base Year of the Analysis||2021|
|Segment Coverage||Product Type, Provider, Model Type, Country|
|Countries Covered||China, Japan, India, South Korea, Australia, Indonesia, Others|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Swine Healthcare Market by Product (Diagnostic Tests, Therapeutics), Disease (Exudative Dermatitis, Coccidiosis, Respiratory Diseases, Swine Dysentery, Porcine Parvovirus, and Others), Route of Administration (Injectable, Oral), Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Online Pharmacy), and Region 2023-2028
Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2023-2028
Congestive Heart Failure Drugs Market by Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2023-2028
Gastric Cancer Drugs Market by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at